Shamir N Kalaria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1427699/publications.pdf

Version: 2024-02-01

1477746 1372195 18 112 10 6 citations h-index g-index papers 19 19 19 149 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy. Pharmaceutical Research, 2022, , .	1.7	1
2	Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy, 2021, 41, 205-211.	1.2	8
3	Evaluation of Switchâ€toâ€Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Realâ€World Retrospective Cohort Study. Clinical Pharmacology and Therapeutics, 2021, 110, 443-451.	2.3	2
4	Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation. International Journal of Cardiology, 2021, 331, 109-113.	0.8	4
5	A prospective, realâ€world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADREâ€02). British Journal of Clinical Pharmacology, 2021, 87, 4375-4385.	1.1	2
6	Evaluation of an ex-vivo neonatal extracorporeal membrane oxygenation circuit on antiepileptic drug sequestration. Perfusion (United Kingdom), 2021, , 026765912110281.	0.5	0
7	Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder. Journal of Clinical Pharmacology, 2021, 61, S117-S124.	1.0	6
8	Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions. Journal of Clinical Pharmacology, 2021, 61, 1324-1333.	1.0	3
9	1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients. Open Forum Infectious Diseases, 2021, 8, S651-S651.	0.4	O
10	An Innovative Diseaseâ€Drugâ€Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate. Clinical and Translational Science, 2020, 13, 88-97.	1.5	5
11	A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	16
12	Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. Pharmacotherapy, 2020, 40, 211-220.	1.2	9
13	Assessment of Similarity in Antipsychotic Exposureâ€Response Relationships in Clinical Trials Between Adults and Adolescents With Acute Exacerbation of Schizophrenia. Journal of Clinical Pharmacology, 2020, 60, 848-859.	1.0	5
14	A Practiceâ€Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADREâ€01). Clinical and Translational Science, 2020, 13, 950-959.	1.5	8
15	Oevelopment of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes (p) Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2365-2370.	1.0	19
16	A Quantitative Justification of Similarity in Placebo Response Between Adults and Adolescents With Acute Exacerbation of Schizophrenia in Clinical Trials. Clinical Pharmacology and Therapeutics, 2019, 106, 1046-1055.	2.3	6
17	Development and validation of a HPLCâ€UV assay for quantification of levetiracetam concentrations in critically ill patients undergoing continuous renal replacement therapy. Biomedical Chromatography, 2018, 32, e4257.	0.8	6
18	Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration. Pharmacotherapy, 2018, 38, e17-e21.	1.2	12